|Articles|January 1, 2004

Pediatric Puzzler: Jaundice and lethargy

Jaundice and lethargy (septo-optic dysplasia or SOD)

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

FDA authorizes first dual glucose-ketone monitor for children as young as 2

FDA authorizes first dual glucose-ketone monitor for children as young as 2

ByMorgan Ebert, Executive Editor

August 25th 2026

FDA approves nipocalimab as first treatment for warm autoimmune hemolytic anemia

FDA approves nipocalimab as first treatment for warm autoimmune hemolytic anemia

ByMorgan Ebert, Executive Editor

August 25th 2026

New multisociety position paper details hospital strategies to close gaps in sepsis care | Image Credit: © Gorodenkoff - stock.adobe.com

New multisociety position paper details hospital strategies to close gaps in sepsis care

ByMorgan Ebert, Executive Editor

August 25th 2026

Lebrikizumab phase 3 data show improvements in atopic dermatitis symptoms, itch in children

Lebrikizumab phase 3 data show improvements in atopic dermatitis symptoms, itch in children

ByLawrence Eichenfield, MD,Contemporary Pediatrics Staff

August 24th 2026

Mental health treatment increases among US children and teens

Mental health treatment increases among US children and teens

ByRaman Baweja, MD, MS

August 24th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

Pediatric mental health treatment rises above prepandemic levels

FDA authorizes first dual glucose-ketone monitor for children as young as 2

Lebrikizumab phase 3 data show improvements in atopic dermatitis symptoms, itch in children

Parent smartphone use linked to slower vocabulary growth in young children

FDA approves nipocalimab as first treatment for warm autoimmune hemolytic anemia